PR in the Philippines

Mumbai, Maharashtra Jul 7, 2025  – In a significant move designed to substantially enhance its research and development capabilities, Dansy Labs has announced the strategic acquisition of key assets and patents located in Hong Kong and Sweden. This acquisition is anticipated to bring about considerable advancements in the company’s global expansion and its innovative research domains, marking a pivotal juncture in its growth trajectory. The long-term strategic investment of USD 120 million for asset buyout and patents in Hong Kong and Sweden includes a comprehensive portfolio of groundbreaking technologies and intellectual properties. These newly acquired assets are set to considerably bolster Dansy Labs’ research and development capacities, thereby accelerating the progress of next-generation products and solutions, as per the company’s statement.

Announcing the USD 120 million investment, Dr. Ashok Tiwari, Managing Director of the unlisted pharmaceutical company Dansy Labs Pvt Limited, stated, “We are delighted to announce that the Board of Directors and Management have approved this crucial proposal during our recent Special General Meeting. This strategic investment will unlock considerable opportunities in key markets, particularly across Sweden. With capital secured from investors and NBFCs, we are prepared to execute this deal and maximize its full potential. The asset buyout and patents form a critical part of Dansy Labs’ broader strategy to extend its global reach. The acquired assets encompass cutting-edge research facilities and advanced technologies that will be integrated into Dansy Labs’ current operations. This expansion is poised to expedite the development of novel pharmaceutical solutions and reinforce the company’s standing as an industry leader. Through this acquisition, Dansy Labs aims to strengthen its innovative capacities and sharpen its competitive edge. The new assets will provide the company with enhanced manufacturing capabilities and resources to drive pioneering research in various therapeutic areas. This strategic maneuver is expected to result in a surge in patent filings and the creation of breakthrough treatments that address unmet medical needs.”

Mr. Chandrakant Patil, Executive Director of Dansy Labs Pvt Limited, commented, “This strategic asset acquisition represents a transformative step for Dansy Labs. It underscores our unwavering dedication to advancing research and innovation within the pharmaceutical industry. By incorporating these world-class assets, we are well-positioned to accelerate the development of cutting-edge therapies and broaden our global footprint. Dansy Labs has consistently been recognized for its commitment to quality and excellence in the pharmaceutical sector. The company’s robust portfolio of active pharmaceutical ingredients (APIs) and intermediates has earned acclaim for its superior quality and efficacy. This latest acquisition further emphasizes Dansy Labs’ commitment to upholding high standards and delivering innovative solutions that improve patient outcomes. The asset buyout is expected to have a profound impact on Dansy Labs’ research and development endeavors. The company plans to leverage the newly acquired assets to explore novel therapeutic pathways and develop treatments that tackle critical health challenges. As Dansy Labs continues to push the boundaries of innovation, it remains dedicated to enhancing the quality of life for patients worldwide. This investment aligns with Dansy Labs’ mission to expand its global presence and solidify its position in the pharmaceutical and healthcare sectors. By integrating these new assets, the company aims to accelerate the development of cutting-edge solutions and maintain its competitive advantage in the industry.”

Dansy Labs Private Limited, with its headquarters in Mumbai, India, is a prominent entity in the pharmaceutical industry. The company specializes in the import and export of active pharmaceutical ingredients (APIs) and intermediates. With a strong emphasis on research and innovation, Dansy Labs is committed to providing high-quality solutions that address the evolving demands of the global healthcare market.

About Dansy Labs

Dansy Labs is a leading global pharmaceutical firm committed to transforming industries through innovation and excellence. With a diverse array of advanced products and solutions in Pharmaceutical APIs, Dansy Labs is dedicated to driving progress and shaping the future of technology. Dansy Labs holds a significant presence in pharmaceutical Active Pharmaceutical Ingredient (API) research, particularly focusing on developing innovative and sustainable methods for producing high-quality APIs, frequently leveraging its expertise in biotechnology, chemistry, and advanced manufacturing technologies; key areas of focus include developing new APIs for complex diseases. Dansy Labs Pvt Ltd, situated in Mumbai—India’s commercial capital—serves as a hub of pharmaceutical research and innovation. Established with the objective of transforming the pharmaceutical landscape, Dansy Labs has established a significant niche for itself in the field of Active Pharmaceutical Ingredient (API) research.

As one of the world’s pioneering API manufacturing and marketing facilities, Dansy Labs Pvt Ltd continues to expand the frontiers of possibilities in pharmaceutical research. The company’s vision is to harness the power of technology and innovation to enhance lives and foster a sustainable future. By concentrating on cutting-edge research and customer-centric development, Dansy Labs is positioned to remain at the forefront of pharmaceutical advancements for years to come.